CoChat
Sign Up
Cited by 42Neuroendocrine Tumor Research AdvancesThyroid Disorders and TreatmentsMedical Case Reports and Studies

Gastrointestinal manifestations of endocrine disease

Open access
Maser, Christina·2006·World Journal of Gastroenterology
DOI 10.3748/wjg.v12.i20.3174PMC PMC4087959
Open this paper in CoChat — free accountOpen PDF

Abstract

The hormonal interactions among the systems throughout the body are not fully understood; many vague clinical symptoms may in fact be manifestations of underlying endocrine diseases. The aim of the following review is to discuss gastrointestinal manifestations of surgically correctable endocrine diseases, focusing on abnormalities of thyroid function, cancer and finally autoimmune diseases. We also review manifestations of pancreatic endocrine tumors, and multiple endocrine neoplasia.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3748/wjg.v12.i20.3174

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Glycosaminoglycans such as hyaluronic acid accumulation is caused by hypothyroidism in the smooth muscles and interstitial tissues of gastrointestinal tract resulting in delayed bowel transit.

    “glycosaminoglycans such as hyaluronic acid accumulation is caused by hypothyroidism in the smooth muscles and interstitial tissues of gastrointestinal tract resulting in delayed bowel transit (Maser et al., 2006).”

    From Thyroid disorders and gastrointestinal dysmotility: an old association (2024) · cites this paper as Maser et al., 2006

    The Functional thyroid disease section says hypothyroidism causes glycosaminoglycan accumulation and that resulting edema in gastric smooth muscle may predispose to gastric dysmotility. It also reports sluggish intestinal motility in hypothyroidism, but does not establish that glycosaminoglycan accumulation throughout gastrointestinal smooth muscle causes delayed bowel transit. Page numbers are unavailable in our copy. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

No references could be resolved yet.

Research works printed but not linked: 56

  1. Wegener M, Wedmann B, Langhoff T, Schaffstein J, Adamek R. Effect of hyperthyroidism on the transit of a caloric solid- liquid meal through the stomach, the small intestine, and the colon in man. J Clin Endocrinol Metab 1992; 75: 745-749
  2. Tinker MB. Discussion of paper by Verbrycke JR. Masked gastrointestinal hyperthyroidism. JAMA 1931; 97: 515-516
  3. Karaus M, Wienbeck M, Grussendorf M, Erckenbrecht JF, Strohmeyer G. Intestinal motor activity in experimental hyperthyroidism in conscious dogs. Gastroenterology 1989; 97: 911-919
  4. Hoogendoorn EH, Cools BM. Hyperthyroidism as a cause of persistent vomiting. Neth J Med 2004; 62: 293-296
  5. Chiu WY, Yang CC, Huang IC, Huang TS. Dysphagia as a manifestation of thyrotoxicosis: report of three cases and literature review. Dysphagia 2004; 19: 120-124
  6. Branski D, Levy J, Globus M, Aviad I, Keren A, Chowers I. Dysphagia as a primary manifestation of hyperthyroidism. J Clin Gastroenterol 1984; 6: 437-440
  7. Bassotti G, Pagliacci MC, Nicoletti I, Pelli MA, Morelli A. Intestinal pseudoobstruction secondary to hypothyroidism. Importance of small bowel manometry. J Clin Gastroenterol 1992; 14: 56-58 www.wjgnet.com
  8. Lu CL, Montgomery P, Zou X, Orr WC, Chen JD. Gastric myoelectrical activity in patients with cervical spinal cord injury. Am J Gastroenterol 1998; 93: 2391-2396
  9. Pfaffenbach B, Adamek RJ, Hagelmann D, Schaffstein J , W e g e n e r M . E f f e c t o f h y p e r t h y r o i d i s m o n a n t r a l myoelectrical activity, gastric emptying and dyspepsia in man. Hepatogastroenterology 1997; 44: 1500-1508
  10. Tenore A, Fasano A, Gasparini N, Sandomenico ML, Ferrara A, Di Carlo A, Guandalini S. Thyroxine effect on intestinal Cl-/ HCO3-exchange in hypo-and hyperthyroid rats. J Endocrinol 1996; 151: 431-437
  11. Thomas FB, Caldwell JH, Greenberger NJ. Steatorrhea in thyrotoxicosis. Relation to hypermotility and excessive dietary fat. Ann Intern Med 1973; 78: 669-675
  12. CRAIL HW. Multiple primary malignancies arising in the rectum, brain, and thyroid; report of a case. U S Nav Med Bull 1949; 49: 123-128
  13. Camiel MR, Mulé JE, Alexander LL, Benninghoff DL. Association of thyroid carcinoma with Gardner's syndrome in siblings. N Engl J Med 1968; 278: 1056-1058
  14. Plail RO, Bussey HJ, Glazer G, Thomson JP. Adenomatous polyposis: an association with carcinoma of the thyroid. Br J Surg 1987; 74: 377-380 16
  15. Perrier ND, van Heerden JA, Goellner JR, Williams ED, Gharib H, Marchesa P, Church JM, Fazio VW, Larson DR. Thyroid cancer in patients with familial adenomatous polyposis. World J Surg 1998; 22: 738-742; discussion 743
  16. Cetta F, Toti P, Petracci M, Montalto G, Disanto A, Lorè F, Fusco A. Thyroid carcinoma associated with familial adenomatous polyposis. Histopathology 1997; 31: 231-236 18
  17. Harach HR, Williams GT, Williams ED. Familial adenomatous polyposis associated thyroid carcinoma: a distinct type of follicular cell neoplasm. Histopathology 1994; 25: 549-561
  18. Hizawa K, Iida M, Yao T, Aoyagi K, Oohata Y, Mibu R, Yamasaki K, Hirata T, Fujishima M. Association between thyroid cancer of cribriform variant and familial adenomatous polyposis. J Clin Pathol 1996; 49: 611-613
  19. Iwama T, Mishima Y, Utsunomiya J. The impact of familial adenomatous polyposis on the tumorigenesis and mortality at the several organs. Its rational treatment. Ann Surg 1993; 217: 101-108
  20. Bülow C, Bülow S. Is screening for thyroid carcinoma indicated in familial adenomatous polyposis? The Leeds Castle Polyposis Group. Int J Colorectal Dis 1997; 12: 240-242
  21. Cetta F, Pelizzo MR, Curia MC, Barbarisi A. Genetics and clinicopathological findings in thyroid carcinomas associated with familial adenomatous polyposis. Am J Pathol 1999; 155: 7-9 23
  22. Cameselle-Teijeiro J, Chan JK. Cribriform-morular variant of papillary carcinoma: a distinctive variant representing the sporadic counterpart of familial adenomatous polyposis- associated thyroid carcinoma? Mod Pathol 1999; 12: 400-411 24
  23. Cetta F, Olschwang S, Petracci M, Montalto G, Baldi C, Zuckermann M, Mariani Costantini R, Fusco A. Genetic alterations in thyroid carcinoma associated with familial adenomatous polyposis: clinical implications and suggestions for early detection. World J Surg 1998; 22: 1231-1236
  24. Ng SB, Sittampalam K, Goh YH, Eu KW. Cribriform-morular variant of papillary carcinoma: the sporadic counterpart of familial adenomatous polyposis-associated thyroid carcinoma. A case report with clinical and molecular genetic correlation. Pathology 2003; 35: 42-46 26
  25. Cetta F, Montalto G, Gori M, Curia MC, Cama A, Olschwang S. Germline mutations of the APC gene in patients with familial adenomatous polyposis-associated thyroid carcinoma: results from a European cooperative study. J Clin Endocrinol Metab 2000; 85: 286-292
  26. Tomoda C, Miyauchi A, Uruno T, Takamura Y, Ito Y, Miya A, Kobayashi K, Matsuzuka F, Kuma S, Kuma K, Kakudo K. Cribriform-morular variant of papillary thyroid carcinoma: clue to early detection of familial adenomatous polyposis- associated colon cancer. World J Surg 2004; 28: 886-889
  27. Sollid LM, Thorsby E. The primary association of celiac disease to a given HLA-DQ alpha/beta heterodimer explains the divergent HLA-DR associations observed in various Caucasian populations. Tissue Antigens 1990; 36: 136-137 29
  28. Dalton TA, Bennett JC. Autoimmune disease and the major histocompatibility complex: therapeutic implications. Am J Med 1992; 92: 183-188
  29. Hakanen M, Luotola K, Salmi J, Laippala P, Kaukinen K, Collin P. Clinical and subclinical autoimmune thyroid disease in adult celiac disease. Dig Dis Sci 2001; 46: 2631-2635
  30. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20: 1161-1181 32
  31. Centanni M, Marignani M, Gargano L, Corleto VD, Casini A, Delle Fave G, Andreoli M, Annibale B. Atrophic body gastritis in patients with autoimmune thyroid disease: an underdiagnosed association. Arch Intern Med 1999; 159: 1726-1730
  32. Segni M, Borrelli O, Pucarelli I, Delle Fave G, Pasquino AM, Annibale B. Early manifestations of gastric autoimmunity in patients with juvenile autoimmune thyroid diseases. J Clin Endocrinol Metab 2004; 89: 4944-4948 34
  33. Hsing AW, Hansson LE, McLaughlin JK, Nyren O, Blot WJ, Ekbom A, Fraumeni JF Jr. Pernicious anemia and subsequent cancer. A population-based cohort study. Cancer 1993; 71: 745-750
  34. Kokkola A, Sjöblom SM, Haapiainen R, Sipponen P, Puolakkainen P, Järvinen H. The risk of gastric carcinoma and carcinoid tumours in patients with pernicious anaemia. A prospective follow-up study. Scand J Gastroenterol 1998; 33: 88-92 36
  35. De Block CE, De Leeuw IH, Bogers JJ, Pelckmans PA, Ieven MM, Van Marck EA, Van Acker KL, Van Gaal LF. Autoimmune gastropathy in type 1 diabetic patients with parietal cell antibodies: histological and clinical findings. Diabetes Care 2003; 26: 82-88
  36. Doppman JL, Chang R, Fraker DL, Norton JA, Alexander HR, Miller DL, Collier E, Skarulis MC, Gorden P. Localization of insulinomas to regions of the pancreas by intra-arterial stimulation with calcium. Ann Intern Med 1995; 123: 269-273
  37. Turner JJ, Wren AM, Jackson JE, Thakker RV, Meeran K. Localization of gastrinomas by selective intra-arterial calcium injection. Clin Endocrinol (Oxf) 2002; 57: 821-825
  38. Proye CA, Lokey JS. Current concepts in functioning endocrine tumors of the pancreas. World J Surg 2004; 28: 1231-1238
  39. Hamoud AK, Khan MF, Aboalmaali N, Usadel KH, Wullstein C, Vogl TJ. Mangan-enhanced MR imaging for the detection and localisation of small pancreatic insulinoma. Eur Radiol 2004; 14: 923-925
  40. Wada M, Komoto I, Doi R, Imamura M. Intravenous calcium injection test is a novel complementary procedure in differential diagnosis for gastrinoma. World J Surg 2002; 26: 1291-1296
  41. Brändle M, Pfammatter T, Spinas GA, Lehmann R, Schmid C. Assessment of selective arterial calcium stimulation and hepatic venous sampling to localize insulin-secreting tumours. Clin Endocrinol (Oxf) 2001; 55: 357-362
  42. Eriksson B, Bergström M, Sundin A, Juhlin C, Orlefors H, Oberg K, Långström B. The role of PET in localization of neuroendocrine and adrenocortical tumors. Ann N Y Acad Sci 2002; 970: 159-169
  43. Assalia A, Gagner M. Laparoscopic pancreatic surgery for islet cell tumors of the pancreas. World J Surg 2004; 28: 1239-1247 46
  44. Thompson GB, Young WF. Multiple Endocrine Neoplasia Type 1. In: Clark OH, Duh Q-Y, Kebebew E, editors. Textbook of Endocrine Surgery, 2 nd edition. Philedelphia: Saunders, 2005: 673-690
  45. B o u k h m a n M P , K a r a m J M , S h a v e r J , S i p e r s t e i n A E , DeLorimier AA, Clark OH. Localization of insulinomas. Arch Surg 1999; 134: 818-822; discussion 822-823
  46. Norton JA, Fraker DL, Alexander HR, Venzon DJ, Doppman JL, Serrano J, Goebel SU, Peghini PL, Roy PK, Gibril F, Jensen RT. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med 1999; 341: 635-644
  47. Imamura M, Minematsu S, Tobe T, Adachi H, Takahashi K. [Selective arterial secretin injection test for localization of gastrinoma]. Nihon Geka Gakkai Zasshi 1986; 87: 671-679
  48. Imamura M, Takahashi K, Adachi H, Minematsu S, Shimada Y, Naito M, Suzuki T, Tobe T, Azuma T. Usefulness of selective arterial secretin injection test for localization of gastrinoma in the Zollinger-Ellison syndrome. Ann Surg 1987; 205: 230-239
  49. Smith SL, Branton SA, Avino AJ, Martin JK, Klingler PJ, Thompson GB, Grant CS, van Heerden JA. Vasoactive intestinal polypeptide secreting islet cell tumors: a 15-year experience and review of the literature. Surgery 1998; 124: 1050-1055
  50. Koch TR, Michener SR, Go VL. Plasma vasoactive intestinal polypeptide concentration determination in patients with diarrhea. Gastroenterology 1991; 100: 99-106s with Diarrhea. Gastroenterology 1991; 100: 99-106
  51. Rindi G, Torsello A, Locatelli V, Solcia E. Ghrelin expression and actions: a novel peptide for an old cell type of the diffuse endocrine system. Exp Biol Med (Maywood) 2004; 229: 1007-1016
  52. Liang H, Wang P, Wang XN, Wang JC, Hao XS. Management of nonfunctioning islet cell tumors. World J Gastroenterol 2004; 10: 1806-1809
  53. Guo KJ, Liao HH, Tian YL, Guo RX, He SG, Shen K. Surgical treatment of nonfunctioning islet cell tumor: report of 41 cases. Hepatobiliary Pancreat Dis Int 2004; 3: 469-472
  54. Skogseid B, Rastad J, Akerstrom G. Pancreatic Endocrine Tumors in Multiple Endocrine Neoplasia Type 1. In Doherty GM and Skogseid B editors Surgical Endocrinology. Philedelphia: Lippincott Williams & Wilkins, 2001
  55. Imamura M. [Treatment for pancreatic endocrine tumors with or without multiple endocrine neoplasia type 1]. Nihon Geka Gakkai Zasshi 2005; 106: 472-478
  56. Cohen MS, Phay JE, Albinson C, DeBenedetti MK, Skinner MA, Lairmore TC, Doherty GM, Balfe DM, Wells SA Jr, Moley JF. Gastrointestinal manifestations of multiple endocrine neoplasia type 2. Ann Surg 2002; 235: 648-654; discussion 654-655

Cited by

Sorted by citations

Authors
Maser, C.
Affiliations
Yale University (US)
Corresponding author
Maser, Christina
ORCID
Maser, Christina
Venue
World Journal of Gastroenterology
Publisher
Baishideng Publishing Group Inc.
Published
2006
Volume
12
Issue
20
Pages
3174
ISSN
1007-9327 (ISSN-L)
DOI
10.3748/wjg.v12.i20.3174
PMC
PMC4087959
OpenAlex
W1518836067
Cited by
42
References
0
Citations by year
2025: 2 · 2024: 2 · 2023: 2 · 2022: 2 · 2021: 2 · 2020: 4 · 2019: 1 · 2018: 5 · 2016: 4 · 2015: 2 · 2014: 2 · 2013: 1 · 2012: 1
FWCI
0.09
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • World Journal of Gastroenterology (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Epidemiology › Neuroendocrine Tumor Research Advances
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
  • Health Sciences › Medicine › Surgery › Medical Case Reports and Studies
Keywords
gastrointestinal manifestations, endocrine disorders, thyroid dysfunction, pancreatic neuroendocrine tumors, multiple endocrine neoplasia, gastrointestinal cancer, autoimmune disease, hormone crosstalk
MeSH terms
Endocrine System Diseases, Gastrointestinal Diseases, Humans, Adenoma, Islet Cell, Thyroid Diseases, Neuroendocrine Tumors, Gastrointestinal Tract

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review